Biotech: Page
-
Courtesy of BioMarin Pharmaceutical
BioMarin pares Roctavian spending as it narrows sales focus
The company plans to limit sales of the hemophilia gene therapy to the U.S., Italy and Germany, while ending most clinical development work.
By Ned Pagliarulo • Aug. 6, 2024 -
Permission granted by Red Queen Therapeutics
Biotech Red Queen launches with $55M to build versatile antivirals
The funding from Apple Tree Partners will help the startup advance an antiviral drug pipeline that includes a COVID treatment nearing mid-stage testing.
By Delilah Alvarado • Aug. 6, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Courtesy of 23andMe
23andMe board rejects CEO Wojcicki’s take-private proposal
A special committee of the board said the proposal offers no premium to 23andMe’s stock price and, with a lack of committed financing, is “insufficient.”
By Elise Reuter • Aug. 2, 2024 -
Getty Images
Vir retreats from infectious disease; Vertex shelves AATD drugs
The one-time drug developer is pivoting to cancer research. Elsewhere, Neurocrine reported a strong quarter and venBio raised half a billion dollars for biotech investing.
By BioPharma Dive staff • Aug. 2, 2024 -
Courtesy of UniQure
UniQure restructuring to claim 300 jobs
The job cuts affect 65% of UniQure’s workforce and include the gene therapy developer’s recent sale of a manufacturing plant to Genezen.
By Delilah Alvarado • Aug. 1, 2024 -
Elizabeth Regan/BioPharma Dive
Otsuka buys startup Jnana, adding to uptick in private biotech M&A
The $800 million deal hands Otsuka a drug that’s shown promise in early testing in phenylketonuria, and is the fourth buyout of a privately held biotech in the last two weeks alone.
By Kristin Jensen • Aug. 1, 2024 -
Getty Images
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
Quarterly sales of Merck’s immunotherapy crested $7 billion for the first time. Elsewhere, Fibrogen is laying off staff and Intellia has a green light to start a new gene editing trial in the U.K.
By BioPharma Dive staff • July 31, 2024 -
Permission granted by AIRNA
Biotech startup Airna raises $60M for RNA editing medicines
Launched last September, the company is working on a treatment for alpha-1 antitrypsin deficiency, which it said could enter the clinic in 2025.
By Gwendolyn Wu • July 31, 2024 -
Permission granted by Incyte
Incyte trims cancer drug pipeline in R&D refocus
The company will stop developing five experimental treatments, including two oral checkpoint inhibitors targeting PD-L1.
By Ned Pagliarulo • July 30, 2024 -
Permission granted by Mubadala Capital
Q&AHow a Mubadala partner views investing in biotech’s new normal
Ayman AlAbdallah discusses some of the inroads the sector has made toward a recovery and the characteristics he looks for in a startup.
By Meagan Parrish • July 29, 2024 -
Courtesy of GSK
GSK leans on Flagship for help finding new drugs, vaccines
The deal resembles recent Flagship alliances with Pfizer and Novo Nordisk, allowing the British pharma to comb through the company creator’s portfolio to unearth up to 10 therapies.
By Gwendolyn Wu • July 29, 2024 -
Getty Images
Ventyx’s TYK2 drug suffers second setback
The company claimed “higher than anticipated” scores from trial volunteers on placebo led to the disappointing data, prompting it to halt internal trials.
By Jonathan Gardner • July 29, 2024 -
Getty Images
NewAmsterdam heart drug hits trial goal, but data appear to disappoint investors
The study is the latest test of a class of cholesterol medicines known as CETP inhibitors, which were abandoned by several large drugmakers last decade.
By Ben Fidler • July 29, 2024 -
Getty Images
Two biotechs cut staff; AbbVie weathers biosimilar threat
Glycomimetics and Cue Biopharma both revealed layoffs. Elsewhere, AbbVie’s earnings impressed Wall Street and an FDA panel recommended changing testing requirements for some lung cancer drugs.
By BioPharma Dive staff • July 26, 2024 -
Elizabeth Regan/BioPharma Dive
Viking shares jump on plans to speed obesity drug into late-stage testing
The drug’s advancement continued what one analyst described as a “torrid” pace for Viking’s closely watched medicine, which started human testing in 2022 and could reach a Phase 3 trial next year.
By Kristin Jensen • July 25, 2024 -
Permission granted by Biogen
Biogen, Sage tremor drug fails key trial
Known as SAGE-324, the drug was one of the key assets Biogen gained rights to through a billion-dollar research deal inked back in 2020.
By Jacob Bell • July 24, 2024 -
Getty Images
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
The Swiss pharma is paying Dren Bio $150 million to partner on “targeted myeloid engagers.” Elsewhere, Geron is losing its commercial chief and Biovectra will sell to Agilent for $925 million.
By BioPharma Dive staff • July 24, 2024 -
Getty Images
Autobahn raises $100M on investor interest in neuropsych drugs
Autobahn’s lead candidate is designed to stimulate thyroid hormone receptors as a way to complement existing antidepressants.
By Gwendolyn Wu • July 24, 2024 -
Peddalanka Ramesh Babu via Getty Images
Startup led by former J&J executives raises $165M for cancer, immune disease drugs
Peter Lebowitz, who for years led J&J’s oncology R&D, is the CEO of the startup, called Third Arc Bio and launched by Omega Funds in 2022.
By Ned Pagliarulo • July 23, 2024 -
Permission granted by Bluebird bio
US government declines to clear Bluebird fertility support for Zynteglo patients
The Health and Human Services' inspector general issued a "negative opinion" on Bluebird's request one week after Vertex sued the federal government over access to fertility preservation services.
By Ned Pagliarulo • July 22, 2024 -
Brian Tucker/BioPharma Dive
Private biotech M&A surges amid difficult IPO market
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
By Gwendolyn Wu • July 22, 2024 -
Permission granted by InterVenn Biosciences
Sponsored by InterVenn BiosciencesBreakthroughs in immunotherapy: glycoproteins as predictive biomarkers for therapeutic response
Serum-based glycoproteins demonstrate success in predicting immune checkpoint inhibitor therapy outcomes.
July 22, 2024 -
Getty Images
Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug
Federal filings showed no companies other than Lilly made an offer to buy Morphic, while Novartis executives said they’re still waiting for more data on pelabresib.
By BioPharma Dive staff • July 19, 2024 -
Getty Images
Immune resetArtiva prices $167M IPO, riding optimism for autoimmune cell therapy
The offering comes days after the publication of a paper showing what analysts said was early proof that “off-the-shelf” cell therapies can treat inflammatory diseases.
By Ben Fidler • July 18, 2024 -
Getty Images
Caribou lays off staff; Roche walks away from Relay
Caribou is slashing its workforce by 12%. Elsewhere, a CDMO is investing in GLP-1 drug demand and Beam’s CFO is returning to J.P. Morgan.
By BioPharma Dive staff • July 17, 2024
Previous
